Published in Cancer Prev Res (Phila) on June 15, 2010
Trial of Aspirin and Arginine Restriction in Colorectal Cancer | NCT00578721
Role of physical activity and diet after colorectal cancer diagnosis. J Clin Oncol (2015) 0.90
The association between NSAID use and colorectal cancer mortality: results from the women's health initiative. Cancer Epidemiol Biomarkers Prev (2012) 0.86
Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer (2013) 0.82
Meat consumption, ornithine decarboxylase gene polymorphism, and outcomes after colorectal cancer diagnosis. J Carcinog (2012) 0.75
Study of the polymorphisms of cyclooxygenase-2 (-765G>C) and 5-lipoxygenase (1708G>A) in patients with colorectal cancer. Oncol Lett (2013) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol (1990) 8.70
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Arginine metabolism: nitric oxide and beyond. Biochem J (1998) 6.44
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med (1994) 5.42
Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control (2001) 5.38
Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer (2004) 4.70
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control (2002) 3.81
Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med (2007) 3.64
A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst (2007) 2.95
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer (2002) 2.60
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res (1996) 2.27
Development of a food frequency questionnaire module and databases for compounds in cooked and processed meats. Mol Nutr Food Res (2005) 2.06
A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis (1991) 2.04
Polyamine metabolism and cancer. J Cell Mol Med (2003) 1.91
Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) (2009) 1.86
Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control (2002) 1.70
Food-derived mutagens and carcinogens. Cancer Res (1992) 1.69
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A (2003) 1.56
Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem (2003) 1.49
Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum (2009) 1.44
Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J (2006) 1.28
Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res (1987) 1.23
Dietary intake of heterocyclic amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev (2001) 1.21
Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer (2009) 1.19
Survival after colorectal cancer diagnosis is associated with colorectal cancer family history. Cancer Epidemiol Biomarkers Prev (2008) 1.18
Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology (1998) 1.16
Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer (2007) 1.12
Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst (2006) 1.11
Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res (2008) 1.04
Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) (2008) 1.03
Development of a polyamine database for assessing dietary intake. J Am Diet Assoc (2007) 1.03
Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res (2009) 1.01
Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models. Biochem Soc Trans (2007) 0.96
The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis. Mol Carcinog (2006) 0.94
Arginine intake, blood pressure, and the incidence of acute coronary events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr (2002) 0.85
Dose-dependent reduction of 3,2'-dimethyl-4-aminobiphenyl-derived DNA adducts in colon and liver of rats administered celecoxib. Mutat Res (2007) 0.78
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med (2006) 7.82
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
A common genetic risk factor for colorectal and prostate cancer. Nat Genet (2007) 7.11
Multiple common variants for celiac disease influencing immune gene expression. Nat Genet (2010) 6.90
Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect (2004) 6.43
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin (2007) 5.67
Exploiting gene-environment interaction to detect genetic associations. Hum Hered (2007) 5.63
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Effect of population-based screening on breast cancer mortality. Lancet (2011) 5.06
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg (2015) 4.78
Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet (2006) 4.78
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control (2008) 4.56
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Increasing burden of melanoma in the United States. J Invest Dermatol (2009) 4.43
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst (2003) 3.83
High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control (2002) 3.81
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer (2013) 3.75
Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol (2005) 3.65
Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol (2010) 3.64
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res (2006) 3.62
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Optimal two-stage genotyping designs for genome-wide association scans. Genet Epidemiol (2006) 3.41
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Consistent association of type 2 diabetes risk variants found in europeans in diverse racial and ethnic groups. PLoS Genet (2010) 3.27
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer (2003) 3.25
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Lung cancer incidence in never smokers. J Clin Oncol (2007) 3.20
Clinically relevant changes in family history of cancer over time. JAMA (2011) 3.18
Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev (2003) 3.11
Influence of individual and combined health behaviors on total and cause-specific mortality in men and women: the United Kingdom health and lifestyle survey. Arch Intern Med (2010) 3.08
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res (2007) 3.08
The landscape of recombination in African Americans. Nature (2011) 3.06
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res (2006) 3.06
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Physical activity levels among breast cancer survivors. Med Sci Sports Exerc (2004) 2.88
Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol (2008) 2.85
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Validation of family history data in cancer family registries. Am J Prev Med (2003) 2.80
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78